美股A股
StockGist
Back
6-K2026-03-13· glm-5

BNR · Burning Rock Biotech Limited

0001193125-26-104743

SEC filing

Summary

Burning Rock Biotech Limited reported unaudited financial results for Q4 and full year 2025, with full-year revenue increasing 4.6% to RMB539.6 million and net loss narrowing significantly to RMB55.3 million from RMB346.6 million in 2024. The company highlighted the granting of a core U.S. patent for its ELSA-seq technology and regulatory progress for its OncoScreen BCMatch Tissue Kit.

Key takeaways